Evidence map›Paper›PMID 41288679›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2026

Epigenetic programming of macrophages across inflammatory and malignant diseases.

Suleiman Ibrahim Mohammad, Hamza Abu Owida, Asokan Vasudevan, Suhas Ballal, Nawaf Alshdaifat, Ali Akberzeda, Abhayveer Singh, Kavitha V, Laxmidhar Maharana, M K Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Suleiman Ibrahim MohammadElectronic Marketing and Social Media, Economic and Administrative Sciences, Zarqa University, Zarqa, Jordan. dr_sliman@yahoo.com.
Hamza Abu OwidaMedical Engineering Department, Faculty of Engineering, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Asokan VasudevanElectronic Marketing and Social Media, Economic and Administrative Sciences, Zarqa University, Zarqa, Jordan.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Nawaf AlshdaifatDepartment of Information Technology, Faculty of Prince Al-Hussein bin Abdullah II of Information Technology, The Hashemite University, Zarqa, Jordan.
Ali AkberzedaCollege of Pharmacy, the Islamic University, Najaf, Iraq.
Abhayveer SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Kavitha VDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Laxmidhar MaharanaDepartment of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha-751030, India.
M K SharmaDepartment of Mathematics, Chaudhary Charan Singh University, Meerut, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophage polarization has been known as a critical step in balancing inflammatory responses by creating a balanced plasticity between M1 and M2 macrophages, which act as pro-inflammatory and anti-inflammatory mediators, respectively. Histone deacetylases (HDACs) have been shown to play a vital role in polarization, identifying them as possible contributors and therapeutic targets in metabolic diseases, cancer, inflammatory diseases, and other associated conditions. In this regard, isoform-specific HDAC inhibitors (HDACis) can selectively alter macrophage polarization, thereby overcoming the limitations of pan-HDAC inhibitors and offering therapeutic advantages. Moreover, combining HDAC inhibitors with other therapies has emerged as a promising approach, especially in cancer; however, further studies should determine the specificity of HDAC inhibitors as well as address possible problems in optimizing the bioavailability and reducing off-target effects and cytotoxicity to translate these results into practical therapeutic plans for disorders associated with inflammation.

Indexed as

Epigenesis, GeneticInflammationMacrophagesNeoplasmsAnimalsHistone Deacetylase InhibitorsHistone DeacetylasesHumansHistone Deacetylase InhibitorsHistone DeacetylasesHDACisHistone deacetylases (HDAC)Immune systemMacrophagePolarization

Identifiers

PMID41288679

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.